Google
GRI 株価分析 — Gri Bio Inc. (Healthcare >> Biotechnology)
GRI に関するよくある質問
GRIのROE（自己資本利益率）は？
Gri Bio Inc.のROEは-103.44%です。
GRIの配当利回りは？
Gri Bio Inc.の配当利回りは0.00%です。
GRIの品質スコア（Quality Score）は？
当社のAIはGRIの総合財務品質を100点中31点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
GRIは今が買い時ですか？
当社AIのタイミングスコアは100点中0点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
GRIはどのセクターに属しますか？
Gri Bio Inc.はHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
GRI AI Analysis Summary
Our AI summary for GRI: Gri Bio Inc. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -103.44%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 1.44
Price
0.06
(4.35%)
Day Change
|
|
|---|
GRI, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.44 |
| PBV / Sector |
0.23 / 44,219.29
GREAT
|
| Earning Per Share | -6.43 |
| PE / Sector |
N/A / 19.28
|
| PEG or PE/Growth / Sector |
N/A / 1.23
|
| Average 1M Daily Value |
0.05 M
GREAT
|
| Average 1W Daily Value |
0.03 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
43% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-04 08:01:36 |
| Symbol | GRI |
| Name | GRI BIO INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 1.77 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 2.44 / 9,645.64 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2223 Avenida de la Playa, La Jolla, CA, United States, 92037
Phone: 619 400 1170
Website: https://www.gribio.com
Sector: Healthcare >> Biotechnology
Description: GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
